Form 4: Jazz Pharmaceuticals CEO Bruce Cozadd Sells Shares Under 10b5-1 Trading Plan

Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, sold a portion of his ordinary shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Bruce C Cozadd, the Chairman and CEO of Jazz Pharmaceuticals plc, executed transactions involving the company's ordinary shares.
• On May 1, 2025, he sold 1,000 ordinary shares at a price of $116.35 per share.
• Following this transaction, Mr. Cozadd directly owns 439,307 ordinary shares.
• On May 2, 2025, he sold 500 ordinary shares at a price of $120 per share.
• Following this transaction, Mr. Cozadd directly owns 438,807 ordinary shares.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports share sales under a pre-arranged trading plan, which is a common practice. There's no indication of positive or negative implications for the company.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 trading plan allows insiders to sell shares without being accused of trading on non-public information. The market will often scrutinize these sales for any potential implications about the company's future performance.

Stakeholder Impact

• Shareholders may react to insider sales, although sales under a 10b5-1 plan are generally viewed as less concerning.

Key Dates

Keywords

Jazz Pharmaceuticals, Bruce Cozadd, share sale, Form 4, 10b5-1 trading plan, ordinary shares, insider trading